Literature DB >> 11884458

Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.

Tazio Storni1, Franziska Lechner, Iris Erdmann, Thomas Bächi, Andrea Jegerlehner, Tilman Dumrese, Thomas M Kündig, Christiane Ruedl, Martin F Bachmann.   

Abstract

Virus-like particles (VLPs) are known to induce strong Ab responses in the absence of adjuvants. In addition, VLPs are able to prime CTL responses in vivo. To study the efficiency of this latter process, we fused peptide p33 derived from lymphocytic choriomeningitis virus to the hepatitis B core Ag, which spontaneously assembles into VLPs (p33-VLPs). These p33-VLPs were efficiently processed in vitro and in vivo for MHC class I presentation. Nevertheless, p33-VLPs induced weak CTL responses that failed to mediate effective protection from viral challenge. However, if APCs were activated concomitantly in vivo using either anti-CD40 Abs or CpG oligonucleotides, the CTL responses induced were fully protective against infection with lymphocytic choriomeningitis virus or recombinant vaccinia virus. Moreover, these CTL responses were comparable to responses generally induced by live vaccines, because they could be measured in primary ex vivo (51)Cr release assays. Thus, while VLPs alone are inefficient at inducing CTL responses, they become very powerful vaccines if applied together with substances that activate APCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884458     DOI: 10.4049/jimmunol.168.6.2880

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming.

Authors:  Stefan Freigang; Denise Egger; Kurt Bienz; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

2.  Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Wei Zhou; Li-Yun Zou
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

3.  Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.

Authors:  Christiane Ruedl; Katrin Schwarz; Andrea Jegerlehner; Tazio Storni; Vania Manolova; Martin F Bachmann
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses.

Authors:  Benjamin J Marsland; Chiara Nembrini; Nicole Schmitz; Brian Abel; Stefan Krautwald; Martin F Bachmann; Manfred Kopf
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

5.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.

Authors:  Rongxin Zhang; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

6.  Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells.

Authors:  Caroline E von Allmen; Nicole Schmitz; Monika Bauer; Heather J Hinton; Michael O Kurrer; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Tim Sparwasser; Roger R Beerli; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

7.  Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.

Authors:  S B Justin Wong; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 9.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

10.  Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells.

Authors:  Heidi Barth; Eva K Schnober; Christoph Neumann-Haefelin; Christine Thumann; Mirjam B Zeisel; Helmut M Diepolder; Zongyi Hu; T Jake Liang; Hubert E Blum; Robert Thimme; Mélanie Lambotin; Thomas F Baumert
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.